NCT05532358View on ClinicalTrials.gov

A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)

PHASE1CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

September 12, 2022

Primary Completion Date

January 28, 2023

Study Completion Date

February 10, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

anle138b (TEV-56286)

Anle138b (TEV-56286) as perpetrator

DRUG

Fluvoxamine 100 mg QD for 5 days

Anle138b (TEV-56286) as victim

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Aptuit

INDUSTRY

collaborator

Quotient Sciences

INDUSTRY

collaborator

Teva Pharmaceutical Industries, Ltd.

INDUSTRY

lead

MODAG GmbH

INDUSTRY

NCT05532358 - A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) | Biotech Hunter | Biotech Hunter